Ak. Blystad et al., High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells, BONE MAR TR, 28(9), 2001, pp. 849-857
Citations number
40
Categorie Soggetti
Hematology,"Medical Research Diagnosis & Treatment
Register data suggest that patients with Hodgkin's disease (HD) given high-
dose therapy (HDT) with peripheral blood progenitor cells (PBPC) have a les
s favourable prognosis as compared to those given bone marrow as stem cell
support. Since this can be due to infusion of tumour cells contaminating th
e PBPC grafts, we initiated a feasibility study in which PBPC grafts from H
D patients were purged by CD34(+) cell enrichment. Controversy exists about
whether the use of CD34(+) enriched stem cells leads to a delayed haematol
ogical and immune reconstitution. We compared these parameters, including r
isk of infections and clinical outcome after HDT, in patients with HD given
either selected CD34+ cells or unmanipulated PBPC as stem cell support. Fr
om October 1994 to May 2000, 40 HD patients with primary refractory disease
or relapse were treated with HDT and supported with either selected CD34() cells (n = 21) or unmanipulated PBPC (n = 19) as stem cell support. All p
atients had chemosensitive disease at the time of transplantation. A median
of 5.8 (range 2.7-20.0) vs 4.5 (range 2.3-17.6) x 10(6) CD34(+) cells per
kilo were reinfused in the CD34(+) group and PBPC group, respectively. No d
ifference was observed between the two groups with regard to time to haemat
ological engraftment, reconstitution of B cells, CD56(+) cells and T cells
at 3 and 12 months and infectious episodes after HDT. Two (5%) treatment-re
lated deaths, one in each group, were observed. The overall survival at 4 y
ears was 86% for the CD34(+) group and 74% for the PBPC group with a median
follow-up of 37 months (range 1-61) and 46 months (range 4-82), respective
ly (P = 0.9). The results of this study demonstrate that the use of CD34(+)
cells is safe and has no adverse effects either with respect to haematolog
ical, immune reconstitution or to infections after HDT.